Anil Taneja has taken on a pivotal leadership role as General Manager – Quality at Mylan, marking another significant milestone in his distinguished pharmaceutical career. With a proven track record of more than 15 years in quality assurance and compliance, Anil brings deep domain expertise in GMP, validation, regulatory frameworks, and quality systems to his new position. This appointment signals Mylan’s continued commitment to upholding the highest global quality standards in drug development and manufacturing.
Anil’s career spans across esteemed pharmaceutical organizations, including Viatris and Dr. Reddy’s Laboratories, where he played instrumental roles in product quality, compliance, and strategic quality initiatives. Known for his hands-on expertise in Quality by Design (QbD), 21 CFR Part 11 compliance, change control, and lean manufacturing systems, Anil has led cross-functional teams in delivering regulatory audits, validation programs, and CAPA systems with precision and agility.
A Gold Medalist and University Topper in B.Pharm from University of Rajasthan, and a top-ranking M.Pharm graduate from Rajiv Gandhi Prodyogiki Vishwavidyalaya, Anil has consistently blended academic brilliance with industry acumen. His certifications as a Certified Quality Manager and in Lean Six Sigma, combined with deep knowledge in SAP, SOPs, and artificial intelligence applications for business, reflect his drive for operational excellence and continuous improvement.
At Mylan, Anil will be responsible for steering quality initiatives that ensure robust compliance with global regulatory expectations. His strategic oversight will span validation, product lifecycle management, cleaning validation, and system enhancements that align with both business goals and patient safety priorities. His deep insight into the pharmaceutical quality ecosystem positions him as a key asset in advancing Mylan’s mission of providing high-quality, affordable medicines worldwide.
With this appointment, Mylan gains a dynamic quality leader whose expertise will undoubtedly reinforce the organization’s global standing in pharmaceutical innovation, compliance, and reliability—delivering greater value to healthcare systems and patients alike.